The use of the drug Elizaria – a biosimilar of the original eculizumab in atypical hemolytic-uremic syndrome due to mutation of the С3 gene in children: clinical observation and literature review
Open Access
- 8 March 2023
- journal article
- research article
- Published by Non-profit organization Nephrology in Nephrology (Saint-Petersburg)
- Vol. 27 (1) , 92-101
Abstract
This article presents the features of atypical haemolytic-uremic syndrome (ORPHA 544472) in children. Atypical haemolytic-uremic syndrome (aHUS) is defined by a triad: haemolytic anaemia, thrombocytopenia and acute kidney injury in pediatric and adult patients. The OMIM catalogue presents the phenotypic series of aHUS with mutations of the C3, CFB, CFH, CFHR1, CFHR3, DGKE, MCP, THBD genes. Atypical haemolytic-uremic syndrome is often associated with gene mutations in proteins and activators that regulate complement. We report the case of a girl who had a manifestation of aHUS at 8 years 5 months of age and a severe relapse at 8 years 10 months of age. The relapse was characterised by manifestations of haemolytic anaemia, thrombocytopenia, acute renal damage, severe arterial hypertension, high lactate dehydrogenase and membrane attack complex levels and low C3 component. After 5 courses of haemodialysis, 3 haemodiafiltration, diuresis increased and biochemical parameters improved. We presented with ASUS in a child associated with a p.Cys1101Tyr C3 gene mutation. We used a complement inhibitor, Elizaria®, a biosimilar to the original drug eculizumab, to treat a child with atypical haemolytic-uremic syndrome due to the C3 gene mutation. The complement system inhibitor therapy with Elizaria preserved the health and life of a sick girl with a severe relapse of aHUS.Keywords
This publication has 17 references indexed in Scilit:
- Phase III Clinical Trial of Elizaria® and Soliris® in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria: Results of Comparative Analysis of Efficacy, Safety, and Pharmacological DataBlood, 2019
- Atypical Hemolytic Uremic Syndrome With the p.Ile1157Thr C3 Mutation Successfully Treated With Plasma Exchange and Eculizumab: A Case ReportCritical Care Explorations, 2019
- Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of JapanClinical and Applied Thrombosis/Hemostasis, 2018
- Disease Recurrence After Early Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome With Complement C3 I1157T MutationJournal of Pediatric Hematology/Oncology, 2016
- aHUS associated with C3 gene mutation: a case with numerous relapses and favorable 20-year outcomePediatric Nephrology, 2015
- Syndrome hémolytique et urémique lié à des anomalies du complémentLa Revue de Médecine Interne, 2011
- Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutationPediatric Nephrology, 2010
- New Treatment Options for Atypical Hemolytic Uremic Syndrome with the Complement Inhibitor EculizumabSeminars in Thrombosis and Hemostasis, 2010
- Complement Inhibitor Eculizumab in Atypical Hemolytic Uremic SyndromeClinical Journal of the American Society of Nephrology, 2009
- Mutations in complement C3 predispose to development of atypical hemolytic uremic syndromeBlood, 2008